In this prospective study on 377 patients, the authors evaluate the effect of the application of a patient-specific transcatheter heart valve (THV) selection algorithm, which suggests the use of a specific THV (CoreValve or SAPIEN XT) for specific anatomical subsets, on procedural outcomes.
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
TAVR (TAVI)
December 2, 2015
This video shows a right axillary Edwards SAPIEN 3 TAVR implanted through the new apical Certitude delivery system, in a patient with severe aortic stenosis. The postoperative follow-up was uneventful and the patient was discharged home on postoperative day three.
October 18, 2015
In this manuscript the authors report on the results of a retrospective propensity score analysis in 102 matched pairs of patients, considered to be in a “grey zone” of surgical risk for either TAVI (Edwards Sapiens, Medtronic CoreValve or Symetis Acurate TA prosthesis) or aortic valve replacement (AVR) with a sutureless prosthesis (Sorin Perceal).
October 8, 2015
The effects of renal failure on outcomes of AVR were examined using CMS data. TAVR pts on dialysis, TAVR pts not on dialysis, and surgical AVR pts on dialysis were compared after propensity score matching. In TAVR patients, dialysis was associated with increased 30 day mortality and survival, and was an independent predictor of worse survival. TAV
October 5, 2015
Patients entered into a clinical trial of TAVR and patients in two registries were evaluated for possible subclinical leaflet thrombosis in their bioprosthetic valves. 40% of the patients in the TAVR trial and 13% of registry patients were found to have such thrombosis. The risk was lower in patients anticoagulated with warfarin. Therpeutic antico
September 30, 2015
In an interview filmed at the 2015 STS Annual Meeting in San Diego, California, Tom Nguyen speaks with Michael Reardon, Chief of Cardiac Surgery at the Methodist DeBakey Heart & Vascular Center in Houston, TX.
September 23, 2015
The authors conducted a propensity-matched analysis of outcomes and costs associated with TAVR vs. SAVR procedures in patients considered either intermediate risk (STS PROM 4-8%) or high risk (STS PROM >8%) within the Commonwealth of Virginia.
September 18, 2015
This study describes activity and outcomes for both standard aortic valve implantation and transcatheter aortic valve implantation (TAVI) in England and Wales in the TAVI era. The study demonstrates that both standard aortic valve implantation and TAVI acitivity have increased since TAVI was first performed in the United Kingdom.
September 4, 2015
Short- and mid-term outcomes of TAVR for nonagenarian (>90 years) patients in the PARTNER-1 trial were assessed for 531 pts. MACE occurred in 35% including stroke in 3.6%. Important paravalvular leak occurred in 1.4%. 30-day mortality was 4% and 3-year mortality was 48%, which compared to 44% in a matched population. QOL stabilized at 6 months
September 3, 2015
The authors of this study compared quality of life in patients at increased surgical risk who underwent either transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR).